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Abstract
Tauopathy  is a pathological hallmark of many neurodegenerative diseases. It is characterized by abnormal
aggregates of pathological phosphotau and somatodendritic redistribution. One suggested strategy for treating 
tauopathy  is to stimulate autophagy, hence, getting rid of these pathological protein aggregates. One key controller
of autophagy is mTOR. Since stimulation of mTOR leads to inhibition of autophagy, inhibitors of mTOR will cause
stimulation of autophagy process. In  this report, tauopathy  was induced in  mice  using annonacin. Blocking
of mTOR was achieved through stereotaxic injection of siRNA  against mTOR. The behavioral and
immunohistochemical evaluation revealed the development of tauopathy  model as proven by deterioration of
behavioral performance in  open field test and significant tau aggregates in  annonacin-treated mice . Blocking
of mTOR revealed significant clearance of tau aggregates in  the injected side; however, tau expression was not
affected by mTOR blockage. © 2018, Springer Science+Business Media, LLC, part of Springer Nature.
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Genetic reduction of mammalian target of rapamycin ameliorates Alzheimer's disease-
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Temsirolimus attenuates tauopathy in vitro and in vivo by targeting tau













Levels of mTOR and its downstream targets 4E-BP1, eEF2, and eEF2 kinase in
relationships with tau in Alzheimer's disease brain
Cited 184 times
View at Publisher
Ludolph, A.C., Kassubek, J., Landwehrmeyer, B.G., Mandelkow, E., Mandelkow, E.-M., Burn, D.J., Caparros-
Lefebvre, D., (...), Wszolek, Z.K.
(2009) European Journal of Neurology, 16 (3), pp. 297-309.  .
doi: 10.1111/j.1468-1331.2008.02513.x
Nicks, J., Lee, S., Harris, A., Falk, D.J., Todd, A.G., Arredondo, K., Dunn Jr., W.A., (...), Notterpek, L.
(2014) Neurobiology of Disease, 70, pp. 224-236.  .
doi: 10.1016/j.nbd.2014.06.023
Ozcelik, S., Fraser, G., Castets, P., Schaeffer, V., Skachokova, Z., Breu, K., Clavaguera, F., (...), Winkler, D.T.
 (Open Access)
(2013) PLoS ONE, 8 (5), art. no. e62459.  .
doi: 10.1371/journal.pone.0062459
Rottscholl, R., Haegele, M., Jainsch, B., Xu, H., Respondek, G., Höllerhage, M., Rösler, T.W., (...), Höglinger,
G.U.
 (Open Access)
(2016) Journal of Neurochemistry, 139 (4), pp. 624-639.  .
doi: 10.1111/jnc.13835
Salama, M., Elhussiny, M., Magdy, A., Omran, A.G., Alsayed, A., Ashry, R., Mohamed, W.
(2018) Metabolic Brain Disease, 33 (2), pp. 583-587.
doi: 10.1007/s11011-017-0137-7
Santacruz, K., Lewis, J., Spires, T., Paulson, J., Kotilinek, L., Ingelsson, M., Guimaraes, A., (...), Ashe, K.H.
(2005) Science, 309 (5733), pp. 476-481.  .
doi: 10.1126/science.1113694
Siman, R., Cocca, R., Dong, Y.
 (Open Access)
(2015) PLoS ONE, 10 (11), art. no. e0142340.  .
doi: 10.1371/journal.pone.0142340
11
Tauopathies with parkinsonism: Clinical spectrum, neuropathologic basis, biological




Rapamycin improves peripheral nerve myelination while it fails to benefit












Chronic consumption of Annona muricata juice triggers and aggravates cerebral tau














The mTOR inhibitor rapamycin mitigates perforant pathway neurodegeneration and
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Mammalian target of rapamycin (mTor) mediates tau protein dyshomeostasis:










Annonacin, a natural lipophilic mitochondrial complex I inhibitor, increases




Rapamycin treatment augments motor neuron degeneration in SOD1  mouse
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